# **GUATEMALA**

#### **BURDEN OF CANCER**



17,581,476

Total # cancer cases (2018)
16,332

Total # cancer deaths (2018)


9,213

Premature deaths from NCDs (2016) 20,305

Cancer as % of NCD premature deaths (2016)

19.6%


## Most common cancer cases (2018)




	9.2%	3.8%	33.6%	4.1%	28.6%	0.8%
PAFS (population attributable fractions)	Tobacco (2017) <sup>a</sup>	Alcohol (2016) <sup>a</sup>	Infections (2012) <sup>b</sup>	Obesity (2012) <sup>b</sup>	UV (2012)°	Occupational risk (2017) <sup>a</sup>
Hactions	<sup>a</sup> PAF, cancer deaths	<sup>b</sup> PAF, cancer cases	<sup>c</sup> PAF, melanoma cases			,

#### **TRENDS**

#### Estimated past and future trends in total cases per year (breast and lung)




#### Probability of premature death from cancer per year




### **INVESTMENT CASE (2019)**

\*Upper middle income



#### Projected lives saved per year



Other childhood cancer

# **GUATEMALA**

° per 10,000 cancer patients  Availability of population-based cancer			WORKFORCE				
egistry (PBCR)**	2019	Registration activity	<sup>a</sup> per 10,000 cancer patients				
Quality of mortality registration***	2007-2016	High	Available staff in Ministry of Health who dedicates significant proportion of their time to cancer	2019	ye		
of external beam radiotherapy	2019	4.9	# of radiation oncologist <sup>a</sup>	2019	n/		
photon, electron) <sup>a</sup>	2019	4.5	# of medical physicist <sup>a</sup>	2019	n/s		
f of mammographs <sup>a</sup>	2020	47.1	# of surgeons <sup>a</sup>	2014	123.		
of CT scanners <sup>a</sup>	2020	56.3	# of radiologist <sup>a</sup>	2019	72.		
of MRI scanners <sup>a</sup>	2020	16.5	# of nuclear medicine physician <sup>a</sup>	2019	2.		
of PET or PET/CT scanners <sup>a</sup>	2020	1.2	# of medical & pathology lab scientists <sup>a</sup>	2018	77.		
FORMULATING RESPONSE							
ntegrated NCD plan	2019	operational	# Public cancer centres per 10,000 cancer patients	2019	1.2		
NCCP (including cancer types)	2019	operational	Early detection programme/ guidelines for 4 cancers (breast, cervix, colon, childhood)	2019	4 cancer(		
MPOWER measures fully implemented and achieved	2018	1	Pathology services	2019	generally availab		
Cancer management guidelines	2019	yes	Bone marrow transplantation capacity	2019	generally no availab		
Palliative care included in their operational, integrated NCD plan	2019	yes	Palliative care availability: community/home-based care	2019	generally no availabl		
f of treatment services (surgery, adiotherapy, chemotherapy)	2019	2	Availability of opioids* for pain management	2015-2017	11		
Breast cancer screening program	2019	yes	*Defined daily doses for statistical purposes (S-DDD) per miliion inha		per day		
Breast cancer screening program: Starting age, target population	2019	25					
GLOBAL INITIATIVES							
Elimination of Cervical Cancer			Global Initiative for Childhood Cancer				
HPV vaccination programme coverage	2018	33	Annual cancer cases (0-14 years old)	2020	87		
Cervical cancer screening	2019	yes	Early detection programme/guidelines	2019	ye		
Screening programme type	2019	opportunistic	Defined referral system	2019	ye		
reening programme method 2019		PAP smear	6				
Screening participation rates 20		10%-50%	Annual cancer cases (0-14 years old)				
arly detection programme/guidelines 201		yes					
- <del>-</del>		•	■ Acute lymphoid leukae		lymphoid leukaemia		
Defined referral system	2019	yes	244 ■ Hodgkin lym		kin lymphoma		
				■ Burkit	t lymphoma		
			484	■ CNS, I	ow grade tumours		
			22	Retino	oblastoma		
			61		tumour		

<sup>\*\*</sup>The incidence estimates for this country have a high degree of uncertainty because they are not based on population based cancer registry